2020
-
Daniel Wallace, MD: Efficacy and safety of evobrutinib in SLE
MEET THE POSTER PRESENTER: This global Phase IIb, randomized, double-blind, placebo-controlled study evaluated the efficacy, dose response, and safety of evobrutinib compared with placebo in adult patients with active autoantibody-positive SLE who received standard of care therapy.
-
Elise van Mulligen, MSc: TARA trial tapering cost-utility analysis
MEET THE POSTER PRESENTER: This is the first randomized controlled trial which included a cost-utility analysis on two active, gradual tapering strategies.
-
Peter Lipsky, MD: Pharmacodynamic effects of iberdomide in active SLE
MEET THE POSTER PRESENTER: Iberdomide is a small molecule, high-affinity ligand of cereblon that has immunomodulatory properties and is currently in development for the treatment of systemic lupus erythematosus (SLE) and multiple myeloma.
-
Johan Dalén: Cost consequences in inflammatory arthritis
MEET THE POSTER PRESENTER: Improved understanding of cost consequences of non-persistence adds a perspective to payers making reimbursement decision.
-
Closing racial/ethnic disparities gap requires concerted effort
It has been well studied and demonstrated that minority race and ethnicity are associated with more severe outcomes in both osteoarthritis and rheumatoid arthritis, and an ACR Convergence 2020 session will explore the contributing factors and how to address them.
-
Answers to common questions often live in uncommon places
This year’s Paul Klemperer, MD Memorial Lecture will provide an example about how following a different path in research can yield important results.
-
Enthesis could guide future inflammatory arthritis treatment breakthroughs
The session will include an overview of the more modern concept of the enthesis organ as an integrated group of tissues functioning to minimize stress.
-
Updated knowledge about rheumatoid factor could reshape RA diagnoses
Emerging data suggests that antibodies and antibody reactivities in RA are far more complex than simply the presence or absence of rheumatoid factor (antibodies against IgG) and anti-CCP, a surrogate for anti-citrullinated protein antibodies (ACPAs).
-
Role of imaging in large vessel vasculitis continues to expand
Proposed classification criteria and management guidelines for large vessel vasculitis (LVV) include imaging, so rheumatologists need to have familiarity with different imaging modalities.
-
Giovanni Adami, MD, PhDc: Glucocorticoids and fracture risk
MEET THE POSTER PRESENTER: Younger patients taking glucocorticoids were at risk of vertebral or hip fractures, while older individuals were at risk of fracture of any kind.